国产含麻类疫苗多剂次接种的安全性评价  

Evaluation on the Safety of Multi-dose Vaccination with Domestic MCV Vaccine

作　　者：梁雪枫[1] 安婧[1] 唐宇[1] LIANG Xue-feng;AN Jing;TANG Yu(Center for Disease Prevention and Control of Lanzhou,Lanzhou,730000,China)

机构地区：[1]甘肃省疾病预防控制中心,兰州730000

出　　处：《中国初级卫生保健》2019年第4期65-66,共2页Chinese Primary Health Care

基　　金：甘肃省卫生行业计划管理项目"含麻疹成分疫苗多剂次接种安全性评价"(GSGL2013-20)

摘　　要：目的评价国产含麻类疫苗(MCV)多剂次接种的安全性。方法通过比较甘肃省2007—2016年MCV疫苗的接种剂次和疑似预防接种异常反应(AEFI)的报告情况,获得第三、四和五剂次接种MCV后AEFI发生情况与麻风-麻腮风疫苗方案之间AEFI差异。结果第三剂次接种麻疹、麻风、麻腮、麻腮风疫苗后的一般反应和(或)异常反应报告发生率均高于麻风-麻腮风两剂接种后的反应发生率,但均在WHO报告的AEFI的发生范围内;由于第四剂次、第五剂次因接种麻腮、麻风和麻腮风剂次均较少,其结果不具有实际指导价值。结论第三剂次接种MCV疫苗选择麻腮或麻腮风疫苗可在相同水平的安全性下,提供腮腺炎发病的控制。第四剂次、第五剂次MCV疫苗安全性选择缺少数据支持。OBJECTIVE To evaluate the safety of multi-dose vaccination of domestic MCV vaccines.METHODS By comparing the inoculation dose of MCV vaccine and the report of AEFI in Gansu Province from 2007 to 2016,the incidence differences of AEFI after third,fourth and fifth doses of MCV between the MR-MMR were obtained.RESULTS The incidence of general reactions and/or abnormal reactions after the third dose of MV,MR,MM,and MMR were higher than that of MR-MMR,but they were all within the scope of the AEFI reported by the WHO;as the fourth dose and the fifth dose of MM,MR,MMR were less frequently due to vaccination,the results had no practical guidance value.CONCLUSION The third dose of MCV vaccine to choose MM or MMR could provide control of the onset of epidemic parotitis at the same level of safety.The fourth dose and the fifth dose of MCV vaccine safety selection lacked data support.

关 键 词：含麻疹成分的疫苗 多剂次 安全性 评价 

分 类 号：R1-9[医药卫生—公共卫生与预防医学]